1. Home
  2. ALT vs MTLS Comparison

ALT vs MTLS Comparison

Compare ALT & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • MTLS
  • Stock Information
  • Founded
  • ALT 1997
  • MTLS 1990
  • Country
  • ALT United States
  • MTLS Belgium
  • Employees
  • ALT N/A
  • MTLS N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • MTLS Computer Software: Prepackaged Software
  • Sector
  • ALT Health Care
  • MTLS Technology
  • Exchange
  • ALT Nasdaq
  • MTLS Nasdaq
  • Market Cap
  • ALT 292.0M
  • MTLS 349.7M
  • IPO Year
  • ALT N/A
  • MTLS 2014
  • Fundamental
  • Price
  • ALT $3.83
  • MTLS $5.13
  • Analyst Decision
  • ALT Strong Buy
  • MTLS
  • Analyst Count
  • ALT 6
  • MTLS 0
  • Target Price
  • ALT $17.40
  • MTLS N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • MTLS 127.2K
  • Earning Date
  • ALT 08-12-2025
  • MTLS 10-23-2025
  • Dividend Yield
  • ALT N/A
  • MTLS N/A
  • EPS Growth
  • ALT N/A
  • MTLS N/A
  • EPS
  • ALT N/A
  • MTLS 0.11
  • Revenue
  • ALT $20,000.00
  • MTLS $311,850,851.00
  • Revenue This Year
  • ALT N/A
  • MTLS $2.98
  • Revenue Next Year
  • ALT $761,880.20
  • MTLS $7.09
  • P/E Ratio
  • ALT N/A
  • MTLS $48.31
  • Revenue Growth
  • ALT N/A
  • MTLS 2.98
  • 52 Week Low
  • ALT $2.90
  • MTLS $3.93
  • 52 Week High
  • ALT $11.16
  • MTLS $9.69
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • MTLS 47.90
  • Support Level
  • ALT $3.35
  • MTLS $5.01
  • Resistance Level
  • ALT $3.66
  • MTLS $5.32
  • Average True Range (ATR)
  • ALT 0.19
  • MTLS 0.18
  • MACD
  • ALT 0.07
  • MTLS 0.02
  • Stochastic Oscillator
  • ALT 86.18
  • MTLS 52.08

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About MTLS Materialise NV

Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.

Share on Social Networks: